Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progr...
glaxosmithkline
June 2022: A small study of rectal cancer patients yielded extraordinary results: 100 percent of the individuals were in remission. The results were published in The New England Journal of Medicine t...
glaxosmithkline